- Cell culture media, essential for supporting the growth and maintenance of cells in vitro, are playing an increasingly critical role in the advancement of biopharmaceuticals, regenerative medicine, and vaccine production across the Asia-Pacific region, driven by surging demand for cell-based research and biologics manufacturing
- The rising demand for cell culture media is primarily fueled by growing investments in pharmaceutical R&D, expanding biotech ecosystems, and government support for life sciences infrastructure, especially in countries such as China, India, South Korea, and Japan
- China dominated the Asia-Pacific cell culture media market with the largest revenue share of 39.2% in 2024, attributed to the rapid scale-up of biologics manufacturing facilities, increasing domestic demand for biosimilars, and favorable regulatory reforms that encourage local production and innovation
- India is expected to be the fastest growing regions in the cell culture media market during the forecast period due to improving healthcare infrastructure, expanding CRO/CDMO activities, and rising clinical trial volume
- The serum-free media segment dominated the Asia-Pacific cell culture media market with a share of 42% in 2024, driven by growing preferences for defined, animal-origin-free formulations that enhance consistency, scalability, and regulatory compliance in advanced biologics production
